BridgeBio Pharma, Inc.
BBIO
$66.54
$2.013.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.54% | -0.46% | -8.65% | 36.83% | -63.57% |
| Total Depreciation and Amortization | 2.65% | 6.15% | 2.57% | -6.07% | -11.12% |
| Total Amortization of Deferred Charges | -67.84% | -- | -- | -- | -61.75% |
| Total Other Non-Cash Items | 17.92% | -11.55% | -3.11% | 55.71% | 328.75% |
| Change in Net Operating Assets | 1,362.05% | -120.24% | 116.72% | -997.38% | 704.34% |
| Cash from Operations | 48.51% | -35.81% | 59.50% | -2.00% | -8.17% |
| Capital Expenditure | 92.98% | 20.88% | -- | -- | 65.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 100.00% |
| Other Investing Activities | -390.25% | 139.76% | -677.93% | 50.00% | -108.31% |
| Cash from Investing | -421.55% | 134.33% | -715.17% | 50.73% | -108.47% |
| Total Debt Issued | -- | -100.00% | -47.83% | 15.00% | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 64.74% | 12.03% | 24.33% | 102.18% | 32.47% |
| Repurchase of Common Stock | -145.62% | -51.63% | 96.01% | -3,464.96% | 2.70% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -35.24% | -88.57% | 72.55% | 58.65% | -- |
| Cash from Financing | -144.07% | -100.30% | 400.66% | -87.27% | 66,934.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.18% | -150.88% | 248.30% | -151.02% | 294.42% |